Compare AstraZeneca plc (AZN) vs Zoom Video Communications, Inc. (ZM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs Zoom Video Communications, Inc. — how do they compare? AstraZeneca plc trades at $168.36 (market cap $253.13B), while Zoom Video Communications, Inc. trades at $92.89 (market cap $26.73B). The key difference: AstraZeneca plc is far larger — about 9.5× Zoom Video Communications, Inc.'s market cap, and AstraZeneca plc pays a 1.92% dividend while Zoom Video Communications, Inc. pays none. Which is the better fit depends on your goals.
| AZN | ZM | |
|---|---|---|
Market Cap | $253.13B | $26.73B |
Sector | Health | Technology |
52-Week High | $209.48 | $111.88 |
52-Week Low | $137.44 | $69.77 |
Enterprise Value | $279.37B | $19.07B |
Dividend Yield | 1.92% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $169.47, down 1.25% amid recent volatility following a Phase III trial failure for Wainua. The stock shows bearish technical signals with key support at $168 and resistance at $170. Fundamentally, the company reported strong 2025 results with revenue of $58.74B and net income of $10.23B, though a recent $1.5B licensing deal for a lung cancer drug highlights ongoing pipeline investments. Analyst sentiment is mixed with 47.5% buy ratings but recent downgrades from firms like HSBC citing trial setbacks.
The outlook balances robust financials against pipeline execution risks. Revenue growth and high margins support valuation, but the Wainua failure raises concerns about future catalysts. Investors should weigh the company's strong cash flow and market position against clinical trial volatility and potential legal investigations. Near-term price action may hinge on Q2 2026 earnings due July 27, 2026.
Zoom Communications (ZM) trades at $91.88, up 2.36% on the day, with a bullish technical signal from moving averages and a neutral RSI. The stock shows strong profitability with a net income margin of 41.99% and a P/E ratio of 13.53, trading below the analyst consensus price target of $118.79. Recent developments include the acquisition of Common Room and expansion of AI-powered Zoom Virtual Agent capabilities, signaling growth initiatives.
The outlook for ZM is positive, supported by robust cash flow, AI integration, and an undervalued stake in Anthropic ahead of its IPO. Risks include competitive pressure from Microsoft and Google, insider selling, and fluctuating cash flow trends. Wall Street sentiment is mixed, with 39% of analysts rating it a buy, but the stock offers value if execution on AI-driven growth continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About Zoom Video Communications, Inc.
Zoom Video Communications, Inc. develops a people-centric cloud service that transforms real-time collaboration experience. The Company offers unified meeting experience, a cloud service that provides a 3-in-1 meeting platform with HD video conferencing, mobility, and web meetings. Zoom Video Communications serves customers worldwide.
Read more on ZM →
